|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shariat SF, Casella R, Khoddami SM,
Hernandez G, Sulser T, Gasser TC and Lerner SP: Urine detection of
survivin is a sensitive marker for the noninvasive diagnosis of
bladder cancer. J Urol. 171:626–630. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Parkin DM: The global burden of urinary
bladder cancer. Scand J Urol Nephrol Suppl. 218:12–20. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kadlubar FF and Badawi AF: Genetic
susceptibility and carcinogen-DNA adduct formation in human urinary
bladder carcinogenesis. Toxicol Lett. 82–83:627–632. 1995.
View Article : Google Scholar
|
|
5
|
Jung I and Messing E: Molecular mechanisms
and pathways in bladder cancer development and progression. Cancer
Control. 7:325–334. 2000.PubMed/NCBI
|
|
6
|
Kaderlik KR and Kadlubar FF: Metabolic
polymorphisms and carcinogen-DNA adduct formation in human
populations. Pharmacogenetics. 5:S108–S117. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bell DA, Taylor JA, Paulson DF, Robertson
CN, Mohler JL and Lucier GW: Genetic risk and carcinogen exposure:
A common inherited defect of the carcinogen-metabolism gene
glutathione S-transferase M1 (GSTM1) that increases susceptibility
to bladder cancer. J Natl Cancer Inst. 85:1159–1164. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar
|
|
9
|
Chiyomaru T, Enokida H, Tatarano S,
Kawahara K, Uchida Y, Nishiyama K, Fujimura L, Kikkawa N, Seki N
and Nakagawa M: miR-145 and miR-133a function as tumour suppressors
and directly regulate FSCN1 expression in bladder cancer. Br J
Cancer. 102:883–891. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ichimi T, Enokida H, Okuno Y, Kunimoto R,
Chiyomaru T, Kawamoto K, Kawahara K, Toki K, Kawakami K, Nishiyama
K and Seki N: Identification of novel microRNA targets based on
microRNA signatures in bladder cancer. Int J Cancer. 125:345–352.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hanke M, Hoefig K, Merz H, et al: A robust
methodology to study urine microRNA as tumor marker: microRNA 126
and microRNA 182 are related to urinary bladder cancer. Urol Oncol.
28:655–661. 2010. View Article : Google Scholar
|
|
12
|
Suzuki-Takahashi I, Kitagawa M, Saijo M,
Higashi H, Ogino H, Matsumoto H, Taya Y, Nishimura S and Okuyama A:
The interactions of E2F with pRB and with p107 are regulated via
the phosphorylation of pRB and p107 by a cyclin-dependent kinase.
Oncogene. 10:1691–1698. 1995.PubMed/NCBI
|
|
13
|
Cordon-Cardo C, Wartinger D, Petrylak D,
Dalbagni G, Fair WR, Fuks Z and Reuter VE: Altered expression of
the retinoblastoma gene product: Prognostic indicator in bladder
cancer. J Natl Cancer Inst. 84:1251–1256. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Habuchi T, Ogawa O, Kakehi Y, Ogura K,
Koshiba M, Sugiyama T and Yoshida O: Allelic loss of chromosome 17p
in urothelial cancer: Strong association with invasive phenotype. J
Urol. 148:1595–1599. 1992.PubMed/NCBI
|
|
15
|
Esrig D, Elmajian D, Groshen S, Freeman
JA, Stein JP, Chen SC, Nichols PW, Skinner DG, Jones PA and Cote
RJ: Accumulation of nuclear p53 and tumor progression in bladder
cancer. N Engl J Med. 331:1259–1264. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Miyao N, Tsai YC, Lerner SP, Olumi AF,
Spruck CH III, Gonzalez-Zulueta M, Nichols PW, Skinner DG and Jones
PA: Role of chromosome 9 in human bladder cancer. Cancer Res.
53:4066–4070. 1993.PubMed/NCBI
|
|
17
|
Kamb A, Gruis NA, Weaver-Feldhaus J, Liu
Q, Harshman K, Tavtigian SV, Stockert E, Day RS III, Johnson BE and
Skolnick MH: A cell cycle regulator potentially involved in genesis
of many tumor types. Science. 264:436–440. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hecker N, Stephan C, Mollenkopf HJ, Jung
K, Preissner R and Meyer HA: A new algorithm for integrated
analysis of miRNA-mRNA interactions based on individual
classification reveals insights into bladder cancer. PloS One.
8:e645432013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fujita A, Sato JR, Rodrigues LO, Ferreira
CE and Sogayar MC: Evaluating different methods of microarray data
normalization. BMC Bioinformatics. 7:4692006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Smyth GK: Limma: Linear models for
microarray data. Bioinformatics and computational biology solutions
using R and Bioconductor. Gentleman R, Carey V, Dudoit S, Irizarry
R and Huber W: Springer; New York: pp. 397–420. 2005
|
|
21
|
Benjamini Y and Hochberg Y: Controlling
the false discovery rate: A practical and powerful approach to
multiple testing. J R Static Soc B Stat Methodol. 1:289–300.
1995.
|
|
22
|
Wang X: miRDB: A microRNA target
prediction and functional annotation database with a wiki
interface. RNA. 14:1012–1017. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang X and El Naqa IM: Prediction of both
conserved and nonconserved microRNA targets in animals.
Bioinformatics. 24:325–332. 2008. View Article : Google Scholar
|
|
24
|
Betel D, Wilson M, Gabow A, Marks DS and
Sander C: The microRNA.org resource: Targets and expression.
Nucleic Acids Res. 36(Database): D149–D153. 2008. View Article : Google Scholar :
|
|
25
|
Szklarczyk D, Franceschini A, Kuhn M,
Simonovic M, Roth A, Minguez P, Doerks T, Stark M, Muller J, Bork
P, et al: The STRING database in 2011: Functional interaction
networks of proteins, globally integrated and scored. Nucleic Acids
Res. 39(Database): D561–D568. 2011. View Article : Google Scholar :
|
|
26
|
Smoot ME, Ono K, Ruscheinski J, Wang PL
and Ideker T: Cytoscape 2.8: New features for data integration and
network visualization. Bioinformatics. 27:431–432. 2011. View Article : Google Scholar :
|
|
27
|
Zhang B, Kirov S and Snoddy J: WebGestalt:
An integrated system for exploring gene sets in various biological
contexts. Nucleic Acids Res. 33(Web Server): W741–W748. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Duncan D, Prodduturi N and Zhang B:
WebGestalt2: An updated and expanded version of the Web-based Gene
Set Analysis Toolkit. BMC Bioinformatics. 11(Suppl 4): 102010.
View Article : Google Scholar
|
|
29
|
Neely LA, Rieger Christ KM, Neto BS, et
al: A microRNA expression ratio defining the invasive phenotype in
bladder tumors. Urol Oncol. 28:39–48. 2010. View Article : Google Scholar
|
|
30
|
Wiklund ED, Bramsen JB, Hulf T, Dyrskjøt
L, Ramanathan R, Hansen TB, Villadsen SB, Gao S, Ostenfeld MS,
Borre M, et al: Coordinated epigenetic repression of the miR-200
family and miR-205 in invasive bladder cancer. Int J Cancer.
128:1327–1334. 2011. View Article : Google Scholar
|
|
31
|
Haber DA: Splicing into senescence: The
curious case of p16 and p19ARF. Cell. 91:555–558. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lloyd AC: p53: Only ARF the story. Nat
Cell Biol. 2:E48–E50. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Berggren P, Kumar R, Sakano S, et al:
Detecting homozygous deletions in the
CDKN2A(p16(INK4a))/ARF(p14(ARF)) gene in urinary bladder cancer
using real-time quantitative PCR. Clin Cancer Res. 9:235–242.
2003.PubMed/NCBI
|
|
34
|
Cordon-Cardo C: Molecular alterations
associated with bladder cancer initiation and progression. Scand J
Urol Nephrol Suppl. 42(s218): 154–165. 2008. View Article : Google Scholar
|
|
35
|
Røtterud R, Nesland JM, Berner A and Fosså
SD: Expression of the epidermal growth factor receptor family in
normal and malignant urothelium. BJU Int. 95:1344–1350. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Veerla S, Lindgren D, Kvist A, Frigyesi A,
Staaf J, Persson H, Liedberg F, Chebil G, Gudjonsson S, Borg A, et
al: MiRNA expression in urothelial carcinomas: Important roles of
miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and
metastasis, and frequent homozygous losses of miR-31. Int J Cancer.
124:2236–2242. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Huang L, Luo J, Cai Q, Pan Q, Zeng H, Guo
Z, Dong W, Huang J and Lin T: MicroRNA-125b suppresses the
development of bladder cancer by targeting E2F3. Int J Cancer.
128:1758–1769. 2011. View Article : Google Scholar
|
|
38
|
Blenkiron C and Miska EA: miRNAs in
cancer: Approaches, aetiology, diagnostics and therapy. Hum Mol
Genet. 16:R106–R113. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ivanovska I, Ball AS, Diaz RL, et al:
MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote
cell cycle progression. Mol Cell Biol. 28:2167–2174. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hershko T and Ginsberg D: Up-regulation of
Bcl-2 homology 3 (BH3)-only proteins by E2F1 mediates apoptosis. J
Biol Chem. 279:8627–8634. 2004. View Article : Google Scholar
|
|
41
|
Ginsberg D: E2F1 pathways to apoptosis.
FEBS Lett. 529:122–125. 2002. View Article : Google Scholar : PubMed/NCBI
|
